About novo nordisk a/s - NONOF
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NONOF At a Glance
Novo Nordisk A/S
Novo Allé 1
Bagsværd, Capital Region 2880
| Phone | 45-44-44-88-88 | Revenue | 46.74B | |
| Industry | Pharmaceuticals: Major | Net Income | 15.49B | |
| Sector | Health Technology | 2025 Sales Growth | 10.972% | |
| Fiscal Year-end | 12 / 2026 | Employees | 68,794 | |
| View SEC Filings |
NONOF Valuation
| P/E Current | 12.799 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 14.67 |
| Price to Sales Ratio | 4.867 |
| Price to Book Ratio | 7.449 |
| Price to Cash Flow Ratio | 12.63 |
| Enterprise Value to EBITDA | 10.772 |
| Enterprise Value to Sales | 5.217 |
| Total Debt to Enterprise Value | 0.084 |
NONOF Efficiency
| Revenue/Employee | 679,358.447 |
| Income Per Employee | 225,161.789 |
| Receivables Turnover | 3.926 |
| Total Asset Turnover | 0.623 |
NONOF Liquidity
| Current Ratio | 0.80 |
| Quick Ratio | 0.57 |
| Cash Ratio | 0.125 |
NONOF Profitability
| Gross Margin | 80.341 |
| Operating Margin | 41.402 |
| Pretax Margin | 42.24 |
| Net Margin | 33.143 |
| Return on Assets | 20.647 |
| Return on Equity | 61.423 |
| Return on Total Capital | 30.31 |
| Return on Invested Capital | 37.969 |
NONOF Capital Structure
| Total Debt to Total Equity | 67.488 |
| Total Debt to Total Capital | 40.294 |
| Total Debt to Total Assets | 24.122 |
| Long-Term Debt to Equity | 61.295 |
| Long-Term Debt to Total Capital | 36.597 |